Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome

Show simple item record

dc.contributor University of Helsinki, Department of Surgery en
dc.contributor University of Helsinki, HUSLAB en
dc.contributor University of Helsinki, HUSLAB en
dc.contributor University of Helsinki, HUS Abdominal Center en
dc.contributor University of Helsinki, HUSLAB en
dc.contributor University of Helsinki, Department of Pathology en
dc.contributor University of Helsinki, HUSLAB en
dc.contributor University of Helsinki, HUS Abdominal Center en
dc.contributor.author Holm, Matilda
dc.contributor.author Joenväärä, Sakari
dc.contributor.author Saraswat, Mayank
dc.contributor.author Mustonen, Harri
dc.contributor.author Tohmola, Tiialotta
dc.contributor.author Ristimäki, Ari
dc.contributor.author Renkonen, Risto
dc.contributor.author Haglund, Caj
dc.date.accessioned 2020-03-05T05:38:03Z
dc.date.available 2020-03-05T05:38:03Z
dc.date.issued 2019-11-02
dc.identifier.citation Holm , M , Joenväärä , S , Saraswat , M , Mustonen , H , Tohmola , T , Ristimäki , A , Renkonen , R & Haglund , C 2019 , ' Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome ' , FASEB BioAdvances , vol. 1 , no. 12 , pp. 723-730 . https://doi.org/10.1096/fba.2019-00062 en
dc.identifier.other PURE: 128053500
dc.identifier.other PURE UUID: b5e1d9a7-b341-4029-a3f0-4608c90ebc70
dc.identifier.other RIS: urn:846CD42362DDDC1A5728DB6425C506ED
dc.identifier.other ORCID: /0000-0001-5632-6796/work/70948143
dc.identifier.other ORCID: /0000-0001-8453-3936/work/76333951
dc.identifier.uri http://hdl.handle.net/10138/313000
dc.description.abstract Abstract Colorectal cancer (CRC) stands for 10% of the worldwide cancer burden and has recently become the second most common cause of cancer death. The 5-year survival rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is widely used to study the plasma proteome, which is complex and contains multitudes of proteins. In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 76 CRC patients. We identified several plasma proteins, such as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant differences in survival, as seen by Cox regression and Kaplan-Meier analysis. Additionally, during Cox regression analysis, samples were adjusted for age and/or tumor stage, enabling stringent analysis. These proteins, although in need of further validation, could be of use during patient follow-up, as their levels can non-invasively be measured from blood samples, and could be of use in predicting patient outcome. Several of these proteins additionally have roles in metabolism and inflammation, two processes central to the development and progression of cancer, further indicating their importance in cancer. en
dc.format.extent 8
dc.language.iso eng
dc.relation.ispartof FASEB BioAdvances
dc.rights en
dc.subject mass spectrometry en
dc.subject outcome en
dc.subject plasma proteome en
dc.subject proteomics en
dc.subject stage en
dc.subject 1182 Biochemistry, cell and molecular biology en
dc.subject 3122 Cancers en
dc.title Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome en
dc.type Article
dc.description.version Peer reviewed
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1096/fba.2019-00062
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/acceptedVersion
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
Holm_et_al_2019_FASEB_BioAdvances.pdf 463.0Kb PDF View/Open
Holm_et_al_2019_FASEB_BioAdvances.pdf 8.464Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record